Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.65 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.65 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21952015 | 0.92 | TSHR (0.70) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL30278759 | 0.92 | TSHR (0.70) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL21952051 | 0.89 | TSHR (0.65) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL21951993 | 0.89 | TSHR (0.65) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL21952032 | 0.87 | TSHR (0.63) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL22009411 | 0.87 | TSHR (0.86) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL21952063 | 0.86 | TSHR (0.62) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL21952024 | 0.86 | TSHR (0.61) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL21952061 | 0.84 | TSHR (0.61) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA | |
| SCHEMBL30278739 | 0.84 | TSHR (0.61) | TSHRAPOBEC3AAPOBEC3GALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880199-B1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUNDACION PUBLICA GALLEGA DE INVESTIG BIOMEDICA INIBIC (ES) | 2025-04-23 | — | — | EP | disclosed |
| CN-115768422-B | Ubiquitin ligase inhibitors for the treatment of cancer | 诺沃亚桑托斯教授基金会 | 2025-03-04 | — | — | CN | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020099652-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2020-05-22 | — | — | WO | disclosed |
| EP-3653208-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | Fundación Profesor Novoa Santos (ES) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653208-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | Fundación Profesor Novoa Santos (ES) | 2020-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | TSHR 4635/4885APOBEC3A 2751/4885APOBEC3G 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.